Centessa Pharmaceuticals (CNTA) Competitors $12.87 +0.25 (+1.98%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$12.88 +0.01 (+0.04%) As of 05/23/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTA vs. BPMC, BBIO, VRNA, TLX, TGTX, GRFS, LNTH, AXSM, NUVL, and LEGNShould you be buying Centessa Pharmaceuticals stock or one of its competitors? The main competitors of Centessa Pharmaceuticals include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma (VRNA), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Axsome Therapeutics (AXSM), Nuvalent (NUVL), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Centessa Pharmaceuticals vs. Blueprint Medicines BridgeBio Pharma Verona Pharma Telix Pharmaceuticals Limited American Depositary Shares TG Therapeutics Grifols Lantheus Axsome Therapeutics Nuvalent Legend Biotech Blueprint Medicines (NASDAQ:BPMC) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability, community ranking and risk. Do institutionals and insiders hold more shares of BPMC or CNTA? 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by insiders. Comparatively, 7.1% of Centessa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is BPMC or CNTA more profitable? Centessa Pharmaceuticals has a net margin of 0.00% compared to Blueprint Medicines' net margin of -13.19%. Centessa Pharmaceuticals' return on equity of -52.13% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Blueprint Medicines-13.19% -77.49% -20.84% Centessa Pharmaceuticals N/A -52.13%-38.01% Do analysts recommend BPMC or CNTA? Blueprint Medicines presently has a consensus price target of $126.56, suggesting a potential upside of 24.69%. Centessa Pharmaceuticals has a consensus price target of $27.00, suggesting a potential upside of 109.79%. Given Centessa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Centessa Pharmaceuticals is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blueprint Medicines 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.83Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor BPMC or CNTA? In the previous week, Blueprint Medicines had 1 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 16 mentions for Blueprint Medicines and 15 mentions for Centessa Pharmaceuticals. Blueprint Medicines' average media sentiment score of 1.34 beat Centessa Pharmaceuticals' score of 1.08 indicating that Blueprint Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Blueprint Medicines 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Centessa Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, BPMC or CNTA? Blueprint Medicines has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Does the MarketBeat Community favor BPMC or CNTA? Blueprint Medicines received 518 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 68.23% of users gave Blueprint Medicines an outperform vote while only 61.02% of users gave Centessa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBlueprint MedicinesOutperform Votes55468.23% Underperform Votes25831.77% Centessa PharmaceuticalsOutperform Votes3661.02% Underperform Votes2338.98% Which has stronger valuation & earnings, BPMC or CNTA? Blueprint Medicines has higher revenue and earnings than Centessa Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlueprint Medicines$562.12M11.66-$67.09M-$2.47-41.09Centessa Pharmaceuticals$15M114.63-$151.09M-$1.81-7.11 SummaryCentessa Pharmaceuticals beats Blueprint Medicines on 10 of the 19 factors compared between the two stocks. Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTA vs. The Competition Export to ExcelMetricCentessa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.72B$6.46B$5.33B$8.31BDividend YieldN/A2.63%5.27%4.10%P/E Ratio-8.418.3626.7119.58Price / Sales114.63258.95395.62135.28Price / CashN/A65.8538.3234.62Price / Book5.326.416.764.50Net Income-$151.09M$143.73M$3.23B$248.40M7 Day Performance2.88%0.31%0.36%-0.85%1 Month Performance-5.44%0.14%7.03%8.09%1 Year Performance55.62%0.31%18.59%8.75% Centessa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTACentessa Pharmaceuticals3.5253 of 5 stars$12.87+2.0%$27.00+109.8%+54.1%$1.72B$15M-8.41200Positive NewsAnalyst UpgradeInsider TradeBPMCBlueprint Medicines1.751 of 5 stars$101.21-0.5%$126.56+25.0%-0.9%$6.54B$562.12M-93.71640Positive NewsInsider TradeAnalyst RevisionBBIOBridgeBio Pharma4.5931 of 5 stars$33.69-0.4%$57.09+69.5%+20.1%$6.40B$127.42M-11.82400Insider TradeVRNAVerona Pharma1.8099 of 5 stars$72.58+1.8%$81.50+12.3%+525.5%$5.88B$118.54M-37.8030Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.54-0.8%$22.00+33.0%N/A$5.59B$783.21M0.00N/AGap DownTGTXTG Therapeutics3.8009 of 5 stars$34.98+1.8%$40.80+16.6%+103.6%$5.55B$386.39M-349.77290Positive NewsGRFSGrifols2.6633 of 5 stars$8.00+3.1%N/A+14.1%$5.50B$7.21B6.8426,300Analyst UpgradeLNTHLantheus4.4439 of 5 stars$78.25-3.7%$132.67+69.5%-6.5%$5.41B$1.54B13.02700Positive NewsAXSMAxsome Therapeutics4.7078 of 5 stars$108.30+0.7%$172.14+59.0%+41.6%$5.33B$432.16M-18.08380Positive NewsAnalyst ForecastInsider TradeNUVLNuvalent2.4641 of 5 stars$73.310.0%$115.50+57.6%+10.2%$5.25BN/A-21.1340News CoveragePositive NewsLEGNLegend Biotech3.6408 of 5 stars$29.11+4.8%$74.73+156.7%-26.8%$5.10B$728.30M-30.641,070 Related Companies and Tools Related Companies BPMC Alternatives BBIO Alternatives VRNA Alternatives TLX Alternatives TGTX Alternatives GRFS Alternatives LNTH Alternatives AXSM Alternatives NUVL Alternatives LEGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTA) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredMemorial Day Sale! 82% Off Disruptors and Dominators!Jensen Huang recently gave the keynote speech at the Consumer Electronics Show in Las Vegas. When the Nvidi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNTA Stock Free CNTA Stock Alerts